Cannabis is the most commonly used illicit drug in the world. However due to a changing legal landscape, and rising interest in therapeutic utility, there is an increasing trend in (long-term) use and possibly, cannabis impairment. Importantly, a growing body of evidence suggests regular cannabis users develop tolerance to the impairing, as well as the rewarding, effects of the drug.
Introduction
Cannabis is the most commonly used illicit drug in the world, with 4% of the global population reportedly using the substance (1). However due to a changing legal landscape, and rising interest in therapeutic utility, there is an increasing trend in (long-term) use (1, 2) . Importantly, a growing body of evidence suggests that the acute effects of cannabis are less prominent in regular cannabis users (3), suggesting development of tolerance to the impairing, as well as the rewarding, effects of the drug. Nonetheless, the neurobiological mechanisms underlying cannabis tolerance are unknown.
Accumulating evidence suggests that the main psychoactive component of cannabis [delta-9tetrahydrocannabinol (THC)] binds to cannabinoid (CB1) receptors located on GABAergic and glutamatergic neurons distributed throughout the brain, with high densities found in limbicreward structures (4). Subsequently, THC has been found to acutely activate the reward circuitry, increasing dopamine (5-9) and glutamate (10, 11) concentration levels in key brain areas including the striatum, nucleus accumbens (NAc) and prefrontal cortex (PFC); a pattern implicated in both the rewarding and impairing effects of drugs of abuse (12, 13) .
Accordingly, studies with chronic cannabis users have found alterations in dopaminergic function in striatal areas (14-16), as well as decreases in glutamate concentrations in the basal ganglia (17, 18) and anterior cingulate cortex (ACC) (19, 20) . Furthermore, repeated use of cannabis has been associated with structural changes in frontal areas, as evinced by decreased grey matter volume (21-23), and abnormal concentrations of metabolites including Nacetylaspartate (NAA), myo-inositol (mI), and choline containing compounds (Cho), biochemical markers of neuronal integrity and glial activation (18, 19, (24) (25) (26) (27) (28) . Taken together, these studies provide evidence that repeated cannabis exposure may lead to alterations in neurotransmission and neuronal health, which underlie the diminished cognitive and behavioral response associated with acute cannabis tolerance. However, to date the neuroadaptations that may underlie cannabis tolerance have not been systematically assessed.
Therefore the aim of the present double-blind, placebo controlled study was twofold. The first goal was to assess acute influence of cannabis in two different cannabis using groups, namely occasional (OUs) and chronic (CUs) users, on brain and behavioral outcomes previously found to be affected by cannabis. To do this, both OUs and CUs received a single cannabis dose containing 300 μ g/kg THC. Ultra-High Field (7T) proton magnetic resonance spectroscopy ( 1 H MRS), a non-invasive imaging technique that allows reliable in vivo measurement of neurometabolites and neurotransmitters, was used to assess glutamate, gamma-aminobutyric acid (GABA), NAA, Cho, and mI levels in the striatum and ACC. Resting state functional magnetic resonance imaging (fMRI) data were acquired to determine functional connectivity between the NAc. Average time courses were obtained for each sphere separately and correlational analysis was performed voxel wise to generate functional connectivity maps for each sphere.
Furthermore, as we were interested in FC within the reward reward circuit, ROI-to-ROI FC was computed according to the same aforementioned procedure, between areas including:
NAc, MDN, VPN, and MC. Fisher's correlation coefficient maps were created between the NAc and MDN, NAc and VPN, MDN and VPN, MDN and MC, and MCand NAc. For further details see SI Methods.
Psychomotor Vigilance Task. The psychomotor vigilance task (PVT) is a sustained-attention, reaction-time task that measures the speed with which participant respond to a visual stimulus (37) . The participant is instructed to press a button as soon as the stimulus appears (red circle).
The outcome measures of the task are response speed (mean reaction time) and number of attentional lapses (reaction time > 500 ms). For more information see SI Methods.
Subjective High. Participants rated their subjective high on visual analogue scales (10 cm) on four consecutive time points after treatment administration. Participants had to indicate how high they felt at that moment, compared with the most high they have ever felt (0=not high at all; 10=extremely high).
Pharmacokinetic Measures. Blood samples (8 mL) to determine cannabinoid concentrations (THC and metabolites OH-THC and THC -COOH) were taken at base-line, 10, 30, 50, and 70 minutes post administration. Blood samples were centrifuged and serum was frozen at −20 °C until analyses for pharmacokinetic assessments. Cannabinoid concentrations were determined using a validated and proficiency test approved forensic routine method consisting of an automated solid-phase extraction and gas chromotrography with tandem mass spectrometric detection with a limit of quantification of 0.3 ng/ml or less (10). 
Statistical

Results
Demographic Characteristics. OUs (n = 12) and CUs (n = 12) did not differ with respect to gender distribution, age, history of cannabis use, or consumption of alcohol, caffeine, nicotine, or other drugs (Table S1 ). As expected, CUs reported using significantly more cannabis per week than OUs.
THC Concentrations in Serum. Mean (SE) concentrations of THC, 11-OH-THC, and THC-COOH in serum are given in Table S2 . As expected from previous experience (38), CUs not only exhibited significantly higher THC-COOH concentrations, but also reached significantly higher THC levels from the same dose regimen than OUs. Figure 1D) ].
Other metabolites did not reach significance (see Table S3 for mean metabolite concentrations). (Table S4 ). No significant differences in activation were found for the inverse comparison (THC > Placebo) in either group.
Furthermore, no significant differences were seen between the left and right NAc seed, so only left NAc seed results are shown. Table S7 . A further voxel wise correlation analysis between NAc FC whole brain correlation coefficient maps and behavioral outcomes was performed, revealing significant positive correlations (all r > .6) in FC between the NAc and cortical brain areas, and behavioral outcomes (Table S8 ).
Exploratory Analysis. In order to assess long-term effects of repeated cannabis exposure, metabolite concentrations, reward circuit FC, and behavioral outcomes during the placebo condition of each group, were compared. The analysis was exploratory in nature, due to the low sample size. No significant difference between groups was found in any of the variables of interest, when controlling for THC and THC-metabolite concentrations in blood (P>.1).
Discussion
The present study demonstrates the first attempt to assess cannabis induced neuroadaptations in the reward system, which may underlie behavioral cannabis tolerance. Using an ultra-high field multimodal brain imaging approach, we showed that in occasional users, cannabis induced significant neurometabolic alterations in the reward circuitry, namely decrements in FC and increments in striatal glutamate, which were associated with increases in subjective high and decreases in performance on a sustained attention task. Such changes were absent in chronic cannabis users. The finding that cannabis altered reward circuitry and distorted behavior in OUs, but not CUs, suggests the development of neuroadaptations in the reward circuitry after excessive use of cannabis that reduce the circuitry and behavioral response to acute cannabis impairment.
The present study found that, in OUs, cannabis decreased coupling between BOLD responses in keys areas of the reward system, a fronto-subcortical network of brain structures that are connected via dopaminergic, GABAergic, and glutamatergic neurotransmission (i.e. nucleus accumbens, VTA, ventral pallidum), motivation and salience attribution (i.e. medial orbital frontal cortex), executive and inhibitory control (i.e. anterior cingulate cortex) and
conditioning and memory (i.e. amygdala, medial orbital frontal cortex, hippocampus) (43, 44).
Importantly, decrements in FC between the NAc and regions such as the thalamus and frontal cortex have been suggested to reflect increases in dopaminergic neurotransmission throughout the circuit (10, 29, 30). Specifically, the NAc receives dopaminergic input from the VTA, which is under inhibitory control of GABA interneurons on which presynaptic CB1 receptors (CB1R) are located. Stimulation of CB1R by THC disinhibits the VTA, which in turn increases dopamine levels in the NAc (45). Subsequently, the increase in striatal dopamine level output from the NAc decreases the GABAergic inhibitory tone to the thalamus, which is reflected in decreased FC, as seen in this study.
Furthermore, this process of disinhibition has been suggested to lead to increased glutamatergic signaling to the prefrontal cortex, subsequently to the VTA, and back to the NAc (30). Accordingly, MRS in OUs showed cannabis increased striatal glutamate concentration levels; a finding that is compatible with previous human studies which have found acute increases (10, 11), as well as chronic decreases (18) The present study also demonstrated that cannabis increased subjective high and decreased performance on a sustained attention task in OUs, outcome variables previously found to be affected by cannabis (10, 31, 32) . Furthermore, behavioral outcomes correlated with striatal functional connectivity to other areas of the reward circuit. Accordingly, cannabis induced changes in striatal glutamate and striatal FC have been significantly associated with decrements in cognitive function and impulse control (30), as well as increases in subjective high (10, 30) and experience of psychotomimetic symptoms (11). Taken together, the findings suggest that the impact of cannabis on neural activity within the reward circuit may underlie multiple behavioral changes observed after acute cannabis exposure.
In line with this, the CUs demonstrated an absence of cannabis induced stimulation of the reward circuit, as well as mitigation of behavioral alterations. Specifically, no changes were seen in either FC between areas of the reward circuitry, or glutamate concentration levels, when comparing cannabis to placebo. Furthermore, sustained attention performance did not significantly differ between treatment conditions. However, CUs reported significantly increased levels of subjective high after cannabis relative to placebo, although the change in high was to a lesser extent than in the OUs, as expected (31). Taken together, findings suggest that chronic cannabis users exhibit pharmacodynamic tolerance to the effects of cannabis.
The mechanisms by which neurobiological tolerance to the acute effects of THC
develops have yet to be fully elucidated. Animal and human research generally supports the notion of CB1R downregulation and desensitization in cortical and subcortical regions after repeated exposure to cannabis (46-53). Although studies have reported global reduction in CB1R availability in chronic cannabis users, it has been suggested that neuroadaptive changes take place in a time and region-specific manner (54), with regional analysis demonstrating significant CB1R decrements in areas such as the ACC and NAc (52). Thus, the absence of change in FC of the NAc with other parts of the reward circuit could suggest that downregulation of CB1 receptors mitigate the impact of acute cannabis intoxication on neural activity within frontosubcortical circuits and associated behavioural outcomes, thus demonstrating the prime mechanisms underlying the development of tolerance in this circuit. However, to further explore the association between CB1 receptor availability and development of tolerance, future studies should assess CB1 receptor availability during acute intoxication.
In order to assess potential long-term effects of repeated cannabis exposure, analyses
were performed comparing the placebo conditions between CUs and OUs on ROI-to-ROI FC within the reward circuit, metabolite concentration levels, and performance on the sustained attention task. Furthermore, as CUs had significantly higher baseline serum THC and THCmetabolite levels than OUs, these values were added as covariates. When controlling for serum concentration levels, no differences were seen between groups on any of the outcome variables.
Absence of group differences are in line with previous PET studies which have found CB1R availability normalization in cannabis dependent users after as little as 2 days of monitored abstinence (51, 53), as well neuropsychological data suggesting reversible cognitive deficits, modulated more by recent exposure than by cumulative lifetime use (55). However, the literature on long-lasting effects of cannabis use is mixed, with studies also reporting long-term changes on brain structure (22, 23), neurometabolite concentration levels (56) 
